Login to your account
Don’t have an account?
Create a Free Accountx
Filter:
Filters applied
- Choice of COVID-19 Vaccines
- Dal-Ré, RafaelRemove Dal-Ré, Rafael filter
- MHRARemove MHRA filter
Publication Date
Please choose a date range between 2021 and 2021.
Collection: Choice of COVID-19 Vaccines
1 Results
- Commentary
When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine
European Journal of Internal MedicineVol. 87p1–2Published online: March 18, 2021- Rafael Dal-Ré
- Rita Banzi
Cited in Scopus: 2Amid an unprecedented surge of COVID-19 cases in the UK, with an increasing number due to a novel more infectious SARS-CoV-2 variant,[1] the UK regulatory agency (MHRA) granted emergency approval to the AstraZeneca COVID-19 vaccine on 30 December 2020. The target population includes adults and elderly. The posology consisting of two separate doses given 4-12 weeks apart. Almost simultaneously, the UK health authorities recommended a dose interval of 12 weeks for both COVID-19 authorized vaccines (Pfizer/BioNTech; AstraZeneca), due to the shortage of doses and to vaccinate the highest number of citizens.
